Clopidogrel in Essential Thrombocythemia
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-12 — CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA): CRETA study rationale (hypothesis/protocol-level, no trial data yet): standard 75 mg/day clopidogrel may give inadequate P2Y12 inhibition in ET due to accelerated platelet turnover and variable CYP-mediated prodrug activation; proposes platelet function testing to identify poor responders and dose escalation to 150 mg/day for thrombosis prevention. (novelty: 3)
Open questions
Related
Contributing findings
CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)
12-jun-2026
novelty 3
per-area 3
introduces